1. Home
  2. HSPO vs KPTI Comparison

HSPO vs KPTI Comparison

Compare HSPO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • KPTI
  • Stock Information
  • Founded
  • HSPO 2014
  • KPTI 2008
  • Country
  • HSPO United States
  • KPTI United States
  • Employees
  • HSPO N/A
  • KPTI N/A
  • Industry
  • HSPO Blank Checks
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • KPTI Health Care
  • Exchange
  • HSPO Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • HSPO 91.5M
  • KPTI 90.7M
  • IPO Year
  • HSPO 2022
  • KPTI 2013
  • Fundamental
  • Price
  • HSPO $11.73
  • KPTI $0.65
  • Analyst Decision
  • HSPO
  • KPTI Strong Buy
  • Analyst Count
  • HSPO 0
  • KPTI 4
  • Target Price
  • HSPO N/A
  • KPTI $5.00
  • AVG Volume (30 Days)
  • HSPO 2.7K
  • KPTI 624.3K
  • Earning Date
  • HSPO 01-01-0001
  • KPTI 02-27-2025
  • Dividend Yield
  • HSPO N/A
  • KPTI N/A
  • EPS Growth
  • HSPO 2.63
  • KPTI N/A
  • EPS
  • HSPO 0.28
  • KPTI N/A
  • Revenue
  • HSPO N/A
  • KPTI $148,442,000.00
  • Revenue This Year
  • HSPO N/A
  • KPTI $5.47
  • Revenue Next Year
  • HSPO N/A
  • KPTI $6.33
  • P/E Ratio
  • HSPO $41.71
  • KPTI N/A
  • Revenue Growth
  • HSPO N/A
  • KPTI 1.77
  • 52 Week Low
  • HSPO $10.77
  • KPTI $0.58
  • 52 Week High
  • HSPO $12.41
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 55.06
  • KPTI 46.93
  • Support Level
  • HSPO $11.68
  • KPTI $0.60
  • Resistance Level
  • HSPO $11.90
  • KPTI $0.70
  • Average True Range (ATR)
  • HSPO 0.10
  • KPTI 0.05
  • MACD
  • HSPO 0.00
  • KPTI 0.00
  • Stochastic Oscillator
  • HSPO 31.31
  • KPTI 49.24

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: